|
1
|
Fletcher CD, Bridge JA, Hogendoorn PC and
Mertens F; World Health Organization, : World Health Organization
Classification of Tumours of Soft Tissue and Bone. 4th edition.
IARC Press; Lyon: pp. 264–274. 2013
|
|
2
|
Chow WA: Chondrosarcoma: biology,
genetics, and epigenetics. F1000Res. 7:F1000 Faculty Rev-1826.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hug EB, Loredo LN, Slater JD, DeVries A,
Grove RI, Schaefer RA, Rosenberg AE and Slater JM: Proton radiation
therapy for chordomas and chondrosarcomas of the skull base. J
Neurosurg. 91:432–439. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hauptman JS, Barkhoudarian G, Safaee M,
Gorgulho A, Tenn S, Agazaryan N, Selch M and De Salles AA:
Challenges in linear accelerator radiotherapy for chordomas and
chondrosarcomas of the skull base: Focus on complications. Int J
Radiat Oncol Biol Phys. 83:542–551. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bloch O and Parsa AT: Skull base
chondrosarcoma: Evidence-based treatment paradigms. Neurosurg Clin
N Am. 24:89–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Debus J, Schulz-Ertner D, Schad L, Essig
M, Rhein B, Thillmann CO and Wannenmacher M: Stereotactic
fractionated radiotherapy for chordomas and chondrosarcomas of the
skull base. Int J Radiat Oncol Biol Phys. 47:591–596. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Amorim Bernstein K, Liebsch N, Chen YL,
Niemierko A, Schwab JH, Raskin K, Lozano-Calderon SA, Cote G,
Harmon DC, Choy E, et al: Clinical outcomes for patients after
surgery and radiation therapy for mesenchymal chondrosarcomas. J
Surg Oncol. 114:982–986. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Amorim Bernstein K and DeLaney T:
Chordomas and chondrosarcomas-The role of radiation therapy. J Surg
Oncol. 114:564–569. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
DeLaney TF, Liebsch NJ, Pedlow FX, Adams
J, Weyman EA, Yeap BY, Depauw N, Nielsen GP, Harmon DC, Yoon SS, et
al: Long-term results of Phase II study of high dose photon/proton
radiotherapy in the management of spine chordomas, chondrosarcomas,
and other sarcomas. J Surg Oncol. 110:115–122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Indelicato DJ, Rotondo RL, Begosh-Mayne D,
Scarborough MT, Gibbs CP, Morris CG and Mendenhall WM: A
prospective outcomes study of proton therapy for chordomas and
chondrosarcomas of the spine. Int J Radiat Oncol Biol Phys.
95:297–303. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Holtzman AL, Rotondo RL, Rutenberg MS,
Indelicato DJ, Mercado CE, Rao D, Tavanaiepour D, Morris CG, Louis
D, Flampouri S, et al: Proton therapy for skull-base
chondrosarcoma, a single-institution outcomes study. J Neurooncol.
142:557–563. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu YH, Wu WS, Lin LC, Liu CS, Ho SY, Wang
BJ, Huang BM, Yeh YL, Chiu HW, Yang WL, et al: Bortezomib enhances
radiosensitivity in oral cancer through inducing autophagy-mediated
TRAF6 oncoprotein degradation. J Exp Clin Cancer Res. 37:912018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cui H, Qin Q, Yang M, Zhang H, Liu Z, Yang
Y, Chen X, Zhu H, Wang D, Meng C, et al: Bortezomib enhances the
radiosensitivity of hypoxic cervical cancer cells by inhibiting
HIF-1α expression. Int J Clin Exp Pathol. 8:9032–9041.
2015.PubMed/NCBI
|
|
14
|
Cacan E, Spring AM, Kumari A, Greer SF and
Garnett-Benson C: Combination treatment with sublethal ionizing
radiation and the proteasome inhibitor, bortezomib, enhances
death-receptor mediated apoptosis and anti-tumor immune Attack. Int
J Mol Sci. 16:30405–30421. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang D, Qin Q, Jiang QJ and Wang DF:
Bortezomib sensitizes esophageal squamous cancer cells to
radiotherapy by suppressing the expression of HIF-1α and apoptosis
proteins. J XRay Sci Technol. 24:639–646. 2016.PubMed/NCBI
|
|
16
|
Lohberger B, Steinecker-Frohnwieser B,
Stuendl N, Kaltenegger H, Leithner A and Rinner B: The proteasome
inhibitor bortezomib affects chondrosarcoma cells via the
mitochondria-caspase dependent pathway and enhances death receptor
expression and autophagy. PLoS One. 11:e01681932016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ryu NE, Lee SH and Park H: Spheroid
culture system methods and applications for mesenchymal stem cells.
Cells. 8:E16202019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Edmondson R, Broglie JJ, Adcock AF and
Yang L: Three-dimensional cell culture systems and their
applications in drug discovery and cell-based biosensors. Assay
Drug Dev Technol. 12:207–218. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Khaitan D and Dwarakanath BS:
Multicellular spheroids as an in vitro model in experimental
oncology: Applications in translational medicine. Expert Opin Drug
Discov. 1:663–675. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dolznig H, Rupp C, Puri C, Haslinger C,
Schweifer N, Wieser E, Kerjaschki D and Garin-Chesa P: Modeling
colon adenocarcinomas in vitro a 3D co-culture system induces
cancer-relevant pathways upon tumor cell and stromal fibroblast
interaction. Am J Pathol. 179:487–501. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Terlizzi M, Le Pechoux C, Salas S, Rapeaud
E, Lerouge D, Sunyach MP, Vogin G, Sole CV, Zilli T, Lutsyk M, et
al: Postoperative radiotherapy in patients with extracranial
chondrosarcoma, a joint study of the French Sarcoma Group and Rare
Cancer Network. Int J Radiat Oncol Biol Phys. 107:726–735. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Girard N, Lhuissier E, Aury-Landas J,
Cauvard O, Lente M, Boittin M, Baugé C and Boumédiene K:
Heterogeneity of chondrosarcomas response to irradiations with
X-rays and carbon ions: A comparative study on five cell lines. J
Bone Oncol. 22:1002832020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Jong Y, Ingola M, Briaire-de Bruijn IH,
Kruisselbrink AB, Venneker S, Palubeckaite I, Heijs BP,
Cleton-Jansen AM, Haas RL and Bovée JV: Radiotherapy resistance in
chondrosarcoma cells; a possible correlation with alterations in
cell cycle related genes. Clin Sarcoma Res. 9:92019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ravi M, Paramesh V, Kaviya SR, Anuradha E
and Solomon FD: 3D cell culture systems: Advantages and
applications. J Cell Physiol. 230:16–26. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barnum KJ and O'Connell MJ: Cell cycle
regulation by checkpoints. Methods Mol Biol. 1170:29–40. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krempler A, Deckbar D, Jeggo PA and
Löbrich M: An imperfect G2M checkpoint contributes to chromosome
instability following irradiation of S and G2 phase cells. Cell
Cycle. 6:1682–1686. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao H, Zhuang Y, Li R, Liu Y, Mei Z, He
Z, Zhou F and Zhou Y: Effects of different doses of X-ray
irradiation on cell apoptosis, cell cycle, DNA damage repair and
glycolysis in HeLa cells. Oncol Lett. 17:42–54. 2019.PubMed/NCBI
|
|
29
|
Marples B, Wouters BG and Joiner MC: An
association between the radiation-induced arrest of G2-phase cells
and low-dose hyper-radiosensitivity: A plausible underlying
mechanism? Radiat Res. 160:38–45. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xing SS, Shen CC, Godard MP, Wang JJ, Yue
YY, Yang ST, Zhao Q, Zhang SB, Wang TX, Yang XL, et al: Bortezomib
inhibits C2C12 growth by inducing cell cycle arrest and apoptosis.
Biochem Biophys Res Commun. 445:375–380. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gu JJ, Kaufman GP, Mavis C, Czuczman MS
and Hernandez-Ilizaliturri FJ: Mitotic catastrophe and cell cycle
arrest are alternative cell death pathways executed by bortezomib
in rituximab resistant B-cell lymphoma cells. Oncotarget.
8:12741–12753. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Edlich F: BCL-2 proteins and apoptosis:
Recent insights and unknowns. Biochem Biophys Res Commun.
500:26–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brunelle JK and Letai A: Control of
mitochondrial apoptosis by the Bcl-2 family. J Cell Sci.
122:437–441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guikema JE, Amiot M and Eldering E:
Exploiting the pro-apoptotic function of NOXA as a therapeutic
modality in cancer. Expert Opin Ther Targets. 21:767–779. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamamoto Y, Tomiyama A, Sasaki N,
Yamaguchi H, Shirakihara T, Nakashima K, Kumagai K, Takeuchi S,
Toyooka T, Otani N, et al: Intracellular cholesterol level
regulates sensitivity of glioblastoma cells against
temozolomide-induced cell death by modulation of caspase-8
activation via death receptor 5-accumulation and activation in the
plasma membrane lipid raft. Biochem Biophys Res Commun.
495:1292e12992018. View Article : Google Scholar
|
|
36
|
Tompkins KD and Thorburn A: Regulation of
apoptosis by autophagy to enhance cancer therapy. Yale J Biol Med.
92:707–718. 2019.PubMed/NCBI
|
|
37
|
Tilija Pun N, Jang WJ and Jeong CH: Role
of autophagy in regulation of cancer cell death/apoptosis during
anti-cancer therapy: Focus on autophagy flux blockade. Arch Pharm
Res. 43:475–488. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mizushima N and Yoshimori T: How to
interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Patterns of MMP-2 and MMP-9 expression in
human cancer cell lines. Oncol Rep. 21:1323–1333. 2009.PubMed/NCBI
|
|
40
|
Brady SW, Zhang J, Tsai MH and Yu D:
PI3K-independent mTOR activation promotes lapatinib resistance and
IAP expression that can be effectively reversed by mTOR and Hsp90
inhibition. Cancer Biol Ther. 16:402–411. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen X, Duan N, Zhang C and Zhang W:
Survivin and tumorigenesis: Molecular mechanisms and therapeutic
strategies. J Cancer. 7:314–323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
de Jong Y, van Oosterwijk JG,
Kruisselbrink AB, Briaire-de Bruijn IH, Agrogiannis G, Baranski Z,
Cleven AH, Cleton-Jansen AM, van de Water B, Danen EH, et al:
Targeting survivin as a potential new treatment for chondrosarcoma
of bone. Oncogenesis. 5:e2222016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kang BH, Plescia J, Song HY, Meli M,
Colombo G, Beebe K, Scroggins B, Neckers L and Altieri DC:
Combinatorial drug design targeting multiple cancer signaling
networks controlled by mitochondrial Hsp90. J Clin Invest.
119:454–464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Du J, Kelly AE, Funabiki H and Patel DJ:
Structural basis for recognition of H3T3ph and Smac/DIABLO
N-terminal peptides by human Survivin. Structure. 20:185–195. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Song K, Shankar E, Yang J, Bane KL,
Wahdan-Alaswad R and Danielpour D: Critical role of a
survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate
epithelial cells. PLoS One. 8:e618962013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Khanna KK and Jackson SP: DNA
double-strand breaks: Signaling, repair and the cancer connection.
Nat Genet. 27:247–254. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fontana AO, Augsburger MA, Grosse N,
Guckenberger M, Lomax AJ, Sartori AA and Pruschy MN: Differential
DNA repair pathway choice in cancer cells after proton- and
photon-irradiation. Radiother Oncol. 116:374–380. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sharma A, Singh K and Almasan A: Histone
H2AX phosphorylation: A marker for DNA damage. Methods Mol Biol.
920:613–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
